Early-Stage Non-Small Cell Lung Cancer: Mitigating the Rigors of ... - Medscape

Mark Socinski, MD, considers the challenges surrounding the identification of patients with early-stage non–small cell lung cancer who do not require adjuvant therapy.

Citing the respective costs of adjuvant chemotherapy and immunotherapy in terms of length of treatment, financial burden, and toxicities, Dr Socinski poses circulating tumor DNA as a possible candidate for determining residual disease, and, though admitting its novel status, predicts that this and other methods in development will allow oncologists to focus treatment strategies to include only what is necessary.

Comments

Popular posts from this blog

I Wish I Didn't Need an Oncologist at All, But I'm Thankful for the One ...

Early symptoms of cancer in males: Common warning signs

20 Famous Men Who Have Had Prostate Cancer